Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024GlobeNewsWire • 05/02/24
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public OfferingGlobeNewsWire • 04/18/24
Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC)GlobeNewsWire • 04/15/24
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and GoalsGlobeNewsWire • 04/08/24
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024GlobeNewsWire • 02/21/24
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™GlobeNewsWire • 01/29/24
Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 12/22/23
UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 12/21/23
Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 12/21/23
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer's DiseaseGlobeNewsWire • 12/20/23
Long-term Survival Data from Longeveron's ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart AssociationGlobeNewsWire • 11/11/23
Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023GlobeNewsWire • 11/03/23
Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ for the Treatment of Mild Alzheimer'sGlobeNewsWire • 10/24/23